A French pharmaceutical giant is acquiring a biotech and its rare immunology disease treatment which is already approved in ...

Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing ...

Sanofi has agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the company aims to expand the company's ...

Morgan Stanley analyst Sarita Kapila resumed coverage of Sanofi (NASDAQ:SNY), assigning an Equal Weight rating and setting a ...

The candidate, named KT-621, is being positioned as a potential oral competitor to Sanofi and Regeneron's blockbuster ...

Here are the five things you need to know, including Lyra's good news, Sanofi's acquisition, Mass. biotech jobs, inside Market Basket's board, AI, and hiring entry-level jobs.

CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with ...

Blueprint Medicines came under pressure from Wall Street on Monday after at least six brokerages downgraded the stock ...

"I'm honored to join the Board of Entrada as it advances its clinical-stage portfolio of Duchenne therapies and its growing ...

ASCO: new Sarclisa data support subcutaneous administration with on-body injector . New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via a ...

Even years later, patients whose symptoms were initially dismissed experience distrust and uncertainty with clinicians.

Tolerance Bio is targeting an often-overlooked organ — the thymus — with cell therapy to help kids with DiGeorge syndrome, and potentially extend lifespan in adults.